Professor Orla Hardiman:

I think the criteria for the use of medicinal cannabis were appropriate and some of my colleagues are involved in the decision-making there. There is definitely a role for medicinal cannabis. As I mentioned earlier, the delays in accessing that are more procedural and relate to the reimbursement systems which, to some extent, has to do with the companies that are involved in the manufacture of medicinal cannabis. It is not within the reach at the present time of myself or the clinical lead programme to resolve that and I think that is going through a process at the moment. However, we would all agree there is definitely a benefit to medicinal cannabis and that the requirements at present are not inappropriate.